Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
| Autor: | Mauro Bafutto, José Roberto de Almeida, Nayle Vilela Leite, Enio Chaves Oliveira, Salustiano Gabriel-Neto, Joffre Rezende-Filho |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Arquivos de Gastroenterologia, Vol 48, Iss 1, Pp 36-40 (2011) |
| Druh dokumentu: | article |
| ISSN: | 1678-4219 0004-2803 |
| DOI: | 10.1590/S0004-28032011000100008 |
| Popis: | CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown. OBJECTIVE: To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. METHODS: Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4). RESULTS: Postinfectious irritable bowel syndrome group presented a statistically significant reduction of the total symptom score (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|